Abbott Carla J, Allen Penelope J, Williams Chris E, Williams Richard A, Epp Stephanie B, Burns Owen, Thomas Ross, Harrison Mark, Thien Patrick C, Saunders Alexia, McGowan Ceara, Sloan Caitlin, Luu Chi D, Nayagam David A X
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia.
Department of Surgery (Ophthalmology), University of Melbourne, East Melbourne, VIC, Australia.
Front Cell Dev Biol. 2024 Jun 20;12:1422764. doi: 10.3389/fcell.2024.1422764. eCollection 2024.
Extraocular electrical stimulation is known to provide neuroprotection for retinal cells in retinal and optic nerve diseases. Currently, the treatment approach requires patients to set up extraocular electrodes and stimulate potentially weekly due to the lack of an implantable stimulation device. Hence, a minimally-invasive implant was developed to provide chronic electrical stimulation to the retina, potentially improving patient compliance for long-term use. The aim of the present study was to determine the surgical and stimulation safety of this novel device designed for neuroprotective stimulation.
Eight normally sighted adult feline subjects were monocularly implanted in the suprachoroidal space in the peripheral retina for 9-39 weeks. Charge balanced, biphasic, current pulses (100 μA, 500 µs pulse width and 50 pulses/s) were delivered continuously to platinum electrodes for 3-34 weeks. Electrode impedances were measured hourly. Retinal structure and function were assessed at 1-, 2-, 4-, 6- and 8-month using electroretinography, optical coherence tomography and fundus photography. Retina and fibrotic thickness were measured from histological sections. Randomized, blinded histopathological assessments of stimulated and non-stimulated retina were performed.
All subjects tolerated the surgical and stimulation procedure with no evidence of discomfort or unexpected adverse outcomes. The device position was stable after a post-surgery settling period. Median electrode impedance remained within a consistent range (5-10 kΩ) over time. There was no change in retinal thickness or function relative to baseline and fellow eyes. Fibrotic capsule thickness was equivalent between stimulated and non-stimulated tissue and helps to hold the device in place. There was no scarring, insertion trauma, necrosis, retinal damage or fibroblastic response in any retinal samples from implanted eyes, whilst 19% had a minimal histiocytic response, 19% had minimal to mild acute inflammation and 28% had minimal to mild chronic inflammation.
Chronic suprathreshold electrical stimulation of the retina using a minimally invasive device evoked a mild tissue response and no adverse clinical findings. Peripheral suprachoroidal electrical stimulation with an implanted device could potentially be an alternative approach to transcorneal electrical stimulation for delivering neuroprotective stimulation.
已知眼外电刺激可为视网膜和视神经疾病中的视网膜细胞提供神经保护。目前,由于缺乏可植入的刺激装置,该治疗方法要求患者设置眼外电极并可能每周进行刺激。因此,开发了一种微创植入物,以向视网膜提供慢性电刺激,可能会提高患者长期使用的依从性。本研究的目的是确定这种用于神经保护性刺激的新型装置的手术和刺激安全性。
八只视力正常的成年猫科动物受试者单眼植入周边视网膜的脉络膜上腔9 - 39周。将电荷平衡、双相电流脉冲(100 μA、500 μs脉冲宽度和50脉冲/秒)连续输送到铂电极3 - 34周。每小时测量电极阻抗。在1、2、4、6和8个月时使用视网膜电图、光学相干断层扫描和眼底摄影评估视网膜结构和功能。从组织学切片测量视网膜和纤维化厚度。对刺激和未刺激的视网膜进行随机、盲法组织病理学评估。
所有受试者均耐受手术和刺激过程,没有不适或意外不良后果的迹象。术后稳定期后装置位置稳定。随着时间的推移,电极阻抗中位数保持在一致范围内(5 - 10 kΩ)。与基线和对侧眼相比,视网膜厚度和功能没有变化。刺激和未刺激组织之间的纤维化囊厚度相当,有助于固定装置。植入眼的任何视网膜样本中均未出现瘢痕形成、插入创伤、坏死、视网膜损伤或成纤维细胞反应,而19%有轻微组织细胞反应,19%有轻微至轻度急性炎症,28%有轻微至轻度慢性炎症。
使用微创装置对视网膜进行慢性阈上电刺激引起轻微的组织反应,且无不良临床发现。植入装置进行周边脉络膜上电刺激可能是经角膜电刺激提供神经保护性刺激的替代方法。